Literature DB >> 31374198

Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.

Mark D McKenzie1, Margherita Ghisi2, Ethan P Oxley2, Steven Ngo2, Luisa Cimmino3, Cécile Esnault4, Ruijie Liu1, Jessica M Salmon2, Charles C Bell5, Nouraiz Ahmed6, Michael Erlichster7, Matthew T Witkowski8, Grace J Liu9, Michael Chopin10, Aleksandar Dakic10, Emilia Simankowicz2, Giovanna Pomilio11, Tina Vu2, Pavle Krsmanovic12, Shian Su1, Luyi Tian7, Tracey M Baldwin1, Daniela A Zalcenstein1, Ladina DiRago13, Shu Wang14, Donald Metcalf15, Ricky W Johnstone5, Ben A Croker16, Graeme I Lancaster17, Andrew J Murphy17, Shalin H Naik7, Stephen L Nutt18, Vitek Pospisil12, Timm Schroeder6, Meaghan Wall19, Mark A Dawson5, Andrew H Wei11, Hugues de Thé4, Matthew E Ritchie20, Johannes Zuber21, Ross A Dickins22.   

Abstract

Tumors are composed of phenotypically heterogeneous cancer cells that often resemble various differentiation states of their lineage of origin. Within this hierarchy, it is thought that an immature subpopulation of tumor-propagating cancer stem cells (CSCs) differentiates into non-tumorigenic progeny, providing a rationale for therapeutic strategies that specifically eradicate CSCs or induce their differentiation. The clinical success of these approaches depends on CSC differentiation being unidirectional rather than reversible, yet this question remains unresolved even in prototypically hierarchical malignancies, such as acute myeloid leukemia (AML). Here, we show in murine and human models of AML that, upon perturbation of endogenous expression of the lineage-determining transcription factor PU.1 or withdrawal of established differentiation therapies, some mature leukemia cells can de-differentiate and reacquire clonogenic and leukemogenic properties. Our results reveal plasticity of CSC maturation in AML, highlighting the need to therapeutically eradicate cancer cells across a range of differentiation states.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PU.1; acute myeloid leukemia; acute promyelocytic leukemia; cancer stem cell; differentiation therapy; leukemia stem cell; myelopoiesis; pioneer factor; retinoic acid; transcription factor

Year:  2019        PMID: 31374198     DOI: 10.1016/j.stem.2019.07.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  24 in total

1.  The ParaHox gene Cdx4 induces acute erythroid leukemia in mice.

Authors:  Silvia Thoene; Tamoghna Mandal; Naidu M Vegi; Leticia Quintanilla-Martinez; Reinhild Rösler; Sebastian Wiese; Klaus H Metzeler; Tobias Herold; Torsten Haferlach; Konstanze Döhner; Hartmut Döhner; Luisa Schwarzmüller; Ursula Klingmüller; Christian Buske; Vijay P S Rawat; Michaela Feuring-Buske
Journal:  Blood Adv       Date:  2019-11-26

2.  Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach.

Authors:  H Hoffmann; C Thiede; I Glauche; M Bornhaeuser; I Roeder
Journal:  J R Soc Interface       Date:  2020-09-09       Impact factor: 4.118

3.  KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.

Authors:  Fangxue Yan; Jinyang Li; Jelena Milosevic; Ricardo Petroni; Suying Liu; Zhennan Shi; Salina Yuan; Janice M Reynaga; Yuwei Qi; Joshua Rico; Sixiang Yu; Yiman Liu; Susumu Rokudai; Neil Palmisiano; Sara E Meyer; Pamela J Sung; Liling Wan; Fei Lan; Benjamin A Garcia; Ben Z Stanger; David B Sykes; M Andrés Blanco
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

Review 4.  Targeting Glioma Stem Cells.

Authors:  Yagmur Muftuoglu; Frank Pajonk
Journal:  Neurosurg Clin N Am       Date:  2021-02-18       Impact factor: 2.509

5.  Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.

Authors:  Eric Wang; Hua Zhou; Bettina Nadorp; Geraldine Cayanan; Xufeng Chen; Anna H Yeaton; Sofia Nomikou; Matthew T Witkowski; Sonali Narang; Andreas Kloetgen; Palaniraja Thandapani; Niklas Ravn-Boess; Aristotelis Tsirigos; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2021-01-14       Impact factor: 24.633

6.  Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.

Authors:  Kyle A Romine; Tamilla Nechiporuk; Daniel Bottomly; Sophia Jeng; Shannon K McWeeney; Andy Kaempf; M Ryan Corces; Ravindra Majeti; Jeffrey W Tyner
Journal:  Blood Cancer Discov       Date:  2021-07-01

7.  Surface protein imputation from single cell transcriptomes by deep neural networks.

Authors:  Zilu Zhou; Chengzhong Ye; Jingshu Wang; Nancy R Zhang
Journal:  Nat Commun       Date:  2020-01-31       Impact factor: 14.919

Review 8.  Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics.

Authors:  Anna S Nam; Ronan Chaligne; Dan A Landau
Journal:  Nat Rev Genet       Date:  2020-08-17       Impact factor: 53.242

Review 9.  Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection.

Authors:  Eric M Pietras; Markus G Manz; Francisco Caiado
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 14.307

Review 10.  Classic and Variants APLs, as Viewed from a Therapy Response.

Authors:  Marie-Claude Geoffroy; Hugues de Thé
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.